MedTrace Logo

A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase

NCT06600659 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2026-02-06

No results posted yet for this study

Summary

This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.

Conditions

  • Hematopoietic and Lymphatic System Neoplasm
  • Acute Lymphobkastic Leukemia

Interventions

OTHER

Non-Interventional Study

Non-interventional study

Sponsors & Collaborators

Principal Investigators

  • Catherine E. Martin, PharmD, RPh · Mayo Clinic in Rochester

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-02
Primary Completion
2026-12-01
Completion
2026-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06600659 on ClinicalTrials.gov